Literature DB >> 1642146

Effects of heparin on osteoclast activity.

M H Chowdhury1, C Hamada, D W Dempster.   

Abstract

The effect of heparin on osteoclastic bone resorption was studied in vitro using the disaggregated osteoclast resorption assay. Bone resorption was assessed by counting the resorption lacunae on bone slices by light microscopy. Low concentrations of heparin (5 micrograms/ml) increased bone resorption by isolated chick and rat osteoclasts. Among other glycosaminoglycans tested at 5 micrograms/ml, only dextran sulfate showed a small but significant stimulation of resorption. Chondroitin sulfates A, B, and C were without effect at 25 and 100 micrograms/ml, whereas resorption was increased by 100 micrograms/ml of heparan sulfate. With chick osteoclasts, which could be maintained in serum-free conditions, a stimulatory effect of heparin was found both in the presence of 5% fetal calf serum and in serum-free media containing insulin, transferrin, and selenium. The magnitude of the heparin-induced increase in resorption was similar in the presence or absence of serum. The stimulation of resorption was associated with an increase in the number of osteoclasts on bone slices. Pretreatment of the bone slices with heparin also enhanced resorption. In time course experiments, 5 micrograms/ml of heparin caused a doubling of chick osteoclast activity index (number of resorption pits per number of osteoclasts) at 12 and 24 h. In 24 h cultures, treatment with 10 micrograms/ml of the arginine-rich basic protein, protamine, 1 microgram/ml of the immunosuppressant, cyclosporine A, or 5 micrograms/ml of the cysteine-proteinase inhibitor, leupeptin, negated the heparin effect on bone resorption. Leupeptin also inhibited basal resorption.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642146     DOI: 10.1002/jbmr.5650070707

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

1.  Bone marrow-derived heparan sulfate potentiates the osteogenic activity of bone morphogenetic protein-2 (BMP-2).

Authors:  Diah S Bramono; Sadasivam Murali; Bina Rai; Ling Ling; Wei Theng Poh; Zophia Xuehui Lim; Gary S Stein; Victor Nurcombe; Andre J van Wijnen; Simon M Cool
Journal:  Bone       Date:  2011-12-28       Impact factor: 4.398

Review 2.  Mast cells in rheumatoid arthritis.

Authors:  Nicola Maruotti; Enrico Crivellato; Francesco Paolo Cantatore; Angelo Vacca; Domenico Ribatti
Journal:  Clin Rheumatol       Date:  2006-05-31       Impact factor: 2.980

3.  Effect of tetracyclines which have metalloproteinase inhibitory capacity on basal and heparin-stimulated bone resorption by chick osteoclasts.

Authors:  M H Chowdhury; S A Moak; B R Rifkin; R A Greenwald
Journal:  Agents Actions       Date:  1993-09

4.  The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin.

Authors:  Gandhi N Solayar; Pauline M Walsh; Kevin J Mulhall
Journal:  BMC Musculoskelet Disord       Date:  2011-10-28       Impact factor: 2.362

Review 5.  Mast cells in inflammatory arthritis.

Authors:  Peter A Nigrovic; David M Lee
Journal:  Arthritis Res Ther       Date:  2004-11-02       Impact factor: 5.156

6.  The Effect of Low Molecular Weight Heparins on Fracture Healing.

Authors:  Stylianos Kapetanakis; Evangelos Nastoulis; Theano Demesticha; Thespis Demetriou
Journal:  Open Orthop J       Date:  2015-06-26

7.  Does Anticoagulant Medication Alter Fracture-Healing? A Morphological and Biomechanical Evaluation of the Possible Effects of Rivaroxaban and Enoxaparin Using a Rat Closed Fracture Model.

Authors:  Peter Michael Prodinger; Rainer Burgkart; Kilian Kreutzer; Franz Liska; Hakan Pilge; Andreas Schmitt; Martina Knödler; Boris Michael Holzapfel; Alexander Hapfelmeier; Thomas Tischer; Oliver Bissinger
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.